

Hepatitis D - Pipeline Insight, 2021

<https://marketpublishers.com/r/H8384061D3BEN.html>

Date: May 2021

Pages: 60

Price: US\$ 1,500.00 (Single User License)

ID: H8384061D3BEN

Abstracts

This report can be delivered to the clients within 48 Hours

DelveInsight's, "Hepatitis D - Pipeline Insight, 2021," report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Hepatitis D pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Hepatitis D Understanding

Hepatitis D : Overview

Hepatitis D, also known as "delta hepatitis," is a liver infection caused by the hepatitis D virus (HDV). Hepatitis D only occurs in people who are also infected with the hepatitis B virus. Hepatitis D is spread when blood or other body fluids from a person infected with the virus enters the body of someone who is not infected. Hepatitis D can be an acute, short-term infection or become a long-term, chronic infection. Hepatitis D can cause severe symptoms and serious illness that can lead to life-long liver damage and even death. People can become infected with both hepatitis B and hepatitis D viruses at the same time (known as "coinfection") or get hepatitis D after first being infected with the hepatitis B virus (known as "superinfection"). There is no vaccine to prevent hepatitis D. However, prevention of hepatitis B with hepatitis B vaccine also protects against future hepatitis D infection.

'Hepatitis D - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Hepatitis D pipeline landscape is provided which includes the disease overview and Hepatitis D treatment guidelines. The assessment part of the report embraces, in depth Hepatitis D commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Hepatitis D collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Hepatitis D R&D. The therapies under development are focused on novel approaches to treat/improve Hepatitis D.

Hepatitis D Emerging Drugs Chapters

This segment of the Hepatitis D report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Hepatitis D Emerging Drugs

Lonafarnib: Eiger Biopharmaceuticals

Lonafarnib is a well-characterized, late-stage, orally active inhibitor of farnesyl transferase, an enzyme involved in modification of proteins through a process called prenylation. HDV uses this host cell process inside liver cells to complete a key step in its life cycle. Lonafarnib inhibits the prenylation step of HDV replication inside liver cells and blocks the virus life cycle at the stage of assembly. Lonafarnib has been dosed in over 120 HDV-infected patients across international academic centers and is in Phase 3 development for HDV with a single, pivotal trial. Lonafarnib has been granted Orphan Drug designation by the U.S. Food and Drug Administration (FDA) and European

Medicines Agency (EMA), and Fast Track and now Breakthrough designation by U.S. FDA. Lonafern is not approved for any indication, and is licensed from Merck Sharp & Dohme Corp. (known as MSD outside of the United States and Canada).

JNJ 73763989: Arrowhead Pharmaceuticals

JNJ 73763989 (formerly ARO HBV) is an RNA interference (RNAi) therapeutic, being developed by Arrowhead Pharmaceuticals for the treatment of patients with hepatitis B and hepatitis D infections.

Further product details are provided in the report

Hepatitis D: Therapeutic Assessment

This segment of the report provides insights about the different Hepatitis D drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Hepatitis D

There are approx. 4+ key companies which are developing the therapies for Hepatitis D. The companies which have their Hepatitis D drug candidates in the most advanced stage, i.e. phase III include, Eiger Biopharmaceuticals.

Phases

DelveInsight's report covers around 4+ products under different phases of clinical development like

Late stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Hepatitis D pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral

Parenteral

intravitreal

Subretinal

Topical.

Molecule Type

Products have been categorized under various Molecule types such as

Monoclonal Antibody

Peptides

Polymer

Small molecule

Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Hepatitis D: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Hepatitis D therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Hepatitis D drugs.

Hepatitis D Report Insights

Hepatitis D Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

Hepatitis D Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing Hepatitis D drugs?

How many Hepatitis D drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Hepatitis D?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Hepatitis D therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Hepatitis D and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

Eiger Biopharmaceuticals

Arrowhead Pharmaceuticals

ContraVir Pharmaceuticals

Antios Therapeutics

PharmaEssentia

REPLICor

SomaGenics

Key Products

Lonafarnib

JNJ 73763989

CRV 431

ATI-2173

Ropeginterferon Alfa-2b (P1101)

REP 2165

Contents

- Introduction
- Executive Summary
- Hepatitis D: Overview
 - Causes
 - Mechanism of Action
 - Signs and Symptoms
 - Diagnosis
 - Disease Management
- Pipeline Therapeutics
 - Comparative Analysis
- Therapeutic Assessment
 - Assessment by Product Type
 - Assessment by Stage and Product Type
 - Assessment by Route of Administration
 - Assessment by Stage and Route of Administration
 - Assessment by Molecule Type
 - Assessment by Stage and Molecule Type
- Hepatitis D – DelveInsight's Analytical Perspective
- In-depth Commercial Assessment
 - Hepatitis D companies' collaborations, Licensing, Acquisition -Deal Value Trends
- Hepatitis D Collaboration Deals
 - Company-Company Collaborations (Licensing / Partnering) Analysis
 - Company-University Collaborations (Licensing / Partnering) Analysis
- Late Stage Products (Phase III)
 - Comparative Analysis
- Lonafarnib: Eiger Biopharmaceuticals
 - Product Description
 - Research and Development
 - Product Development Activities
- Drug profiles in the detailed report
- Mid Stage Products (Phase II)
 - Comparative Analysis
- JNJ 73763989: Arrowhead Pharmaceuticals
 - Product Description
 - Research and Development
 - Product Development Activities
- Drug profiles in the detailed report

Inactive Products

Comparative Analysis

Hepatitis D Key Companies

Hepatitis D Key Products

Hepatitis D- Unmet Needs

Hepatitis D- Market Drivers and Barriers

Hepatitis D- Future Perspectives and Conclusion

Hepatitis D Analyst Views

Hepatitis D Key Companies

Appendix

List Of Tables

LIST OF TABLES

Table 1 Total Products for Hepatitis D

Table 2 Late Stage Products

Table 3 Mid Stage Products

Table 4 Early Stage Products

Table 5 Pre-clinical & Discovery Stage Products

Table 6 Assessment by Product Type

Table 7 Assessment by Stage and Product Type

Table 8 Assessment by Route of Administration

Table 9 Assessment by Stage and Route of Administration

Table 10 Assessment by Molecule Type

Table 11 Assessment by Stage and Molecule Type

Table 12 Inactive Products

List Of Figures

LIST OF FIGURES

- Figure 1 Total Products for Hepatitis D
- Figure 2 Late Stage Products
- Figure 3 Mid Stage Products
- Figure 4 Early Stage Products
- Figure 5 Preclinical and Discovery Stage Products
- Figure 6 Assessment by Product Type
- Figure 7 Assessment by Stage and Product Type
- Figure 8 Assessment by Route of Administration
- Figure 9 Assessment by Stage and Route of Administration
- Figure 10 Assessment by Molecule Type
- Figure 11 Assessment by Stage and Molecule Type
- Figure 12 Inactive Products

I would like to order

Product name: Hepatitis D - Pipeline Insight, 2021

Product link: <https://marketpublishers.com/r/H8384061D3BEN.html>

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/H8384061D3BEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970